On August 20, INSILICO rose 7.05% in regular trading, trading at HK$43.28/share, with turnover of HK$235 million. The stock rebounded sharply after two consecutive sessions of decline totaling approximately 10%, triggered by the company's announcement to invest over RMB 300 million in a RMB 1.01 billion biomedical fund.

Multiple catalysts are supporting the rebound. The company was added to the MSCI Global Small Cap Indexes effective after market close on August 31, with passive fund allocation expectations providing buying support. Additionally, with mid-term results scheduled for August 26, the market expects first-half revenue to surge over 270% year-on-year with a turnaround to profitability, bolstering sentiment.

Within the Life Sciences Tools and Services sector, the broader sector showed strength. Among individual stocks, GENSCRIPT BIO up 11.92%, XTALPI up 12.24%, WUXI BIO up 2.84%, WUXI APPTEC up 2.77%, WUXI XDC up 1.91%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)